Skip to main content

Illumina Inc(ILMN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low131.01
Day High137.79
Open:133.20
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
Futures-options traders work on the floor at the New York Stock Exchange's NYSE American (AMEX) in New York City, U.S., April 13, 2026. REUTERS/Brendan McDermid
the globe and mail

Market Factors: ‘Perfect’ stocks to hold for current geopolitical chaos

Plus, why oil price increases are less dangerous to the economy
Tipranks
Barclays Keeps Their Sell Rating on Illumina (ILMN)
StockStory
3 Unpopular Stocks That Concern Us
CHH
StockStory
3 Reasons to Avoid ILMN and 1 Stock to Buy Instead
ILMN
Tipranks
Illumina Announces Board Retirements and New Director Nominee
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Kyverna Therapeutics, Inc. (KYTX) and Monopar Therapeutics Inc (MNPR)
StockStory
1 Mid-Cap Stock for Long-Term Investors and 2 We Brush Off
ZM
StockStory
RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know
RDNT
Motley Fool
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop
StockStory
Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders
ILMN
Zacks Investment Research
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?
Tipranks
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX) and Illumina (ILMN)
StockStory
3 Profitable Stocks with Open Questions
SGI
Tipranks
Bank of America Securities Reaffirms Their Sell Rating on Illumina (ILMN)
Motley Fool
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally
Tipranks
Guggenheim Keeps Their Buy Rating on Illumina (ILMN)
Tipranks
Illumina (ILMN) Gets a Hold from Canaccord Genuity
StockStory
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
REGN
StockStory
5 Insightful Analyst Questions From Illumina’s Q4 Earnings Call
ILMN
Tipranks
Illumina Earnings Call Highlights Clinical Growth Momentum
Tipranks
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL)
Tipranks
Illumina (ILMN) Gets a Buy from Stifel Nicolaus
Tipranks
Guggenheim Reaffirms Their Buy Rating on Illumina (ILMN)
Tipranks
Illumina (ILMN) Gets a Sell from Barclays
Motley Fool
Could Nvidia Be the Best Way to Play the AI Boom in 2026?
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN), Veeva Systems (VEEV)
StockStory
ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum
ILMN
Motley Fool
Illumina (ILMN) Q4 2025 Earnings Call Transcript
StockStory
Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025
ILMN
StockStory
Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings
ILMN
Tipranks
Illumina Completes SomaLogic Acquisition, Expands Proteomics Capabilities
GlobeNewswire
Standard BioTools Completes Sale of SomaLogic to Illumina
StockStory
Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest
ILMN

Profile

Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.